Investigation reveals increased asthma hospitalizations in children, prompting approval of Flovent HFA generic version.
After a Senate investigation into GSK's discontinuation of the Flovent HFA inhaler in 2024 and the subsequent increase in hospitalizations of children with asthma, a generic version of the inhaler is now available. Flovent HFA remains off the market.
No takes yet. Share an insight, caveat, or question.
Diane S. Aschenbrenner (2026) studied this question.
Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context: